TaiGen Biopharmaceutical (太景-KY)* has signed an exclusive commercialization agreement with Boryung Biopharma for its antiviral drug Pixavir marboxil (TG-1000) in South Korea.

• Deal Structure: Boryung secures exclusive development and sales rights in South Korea, while TaiGen receives an upfront payment, milestones, and post-launch royalties.
• Market Dynamics: South Korea saw a record 3.1 million flu cases in 2023, with 63% of patients under the age of 19.
• Competitive Advantage: While Oseltamivir (Tamiflu) requires a five-day regimen, Pixavir requires only a single dose. This significantly improves compliance among pediatric and adolescent populations, positioning it as a preferred choice for clinicians and parents.
• Global Strategy: Chairman Huang Kuo-lung noted that following China and India, South Korea is a key "piece of the puzzle" in TaiGen's global licensing strategy, which now targets the US, Japan, and MENA regions.

Resource: 太景流感新藥 海外報捷